$ACOG.v DD Shares of Alpha Cognition (TSXV: ACOG) saw an increase in positive volume last week equal to levels the stock saw right before it rose 19.32% earlier this month.
The company’s stock recently broke out of a bearish trend into consolidation as well and is stabilizing strongly at the 50MA. This is a great sign that investors are waiting for a good catalyst to buy. And oh boy, there are a lot of catalysts on the horizon.
iA Capital has maintained a strong speculative buy position on the pre-revenue company, stating that it is “catalyst rich”. Additionally, Raymond James is sticking with its position on the company with a target price of $3.50.
Based on a four percent probability adjustment, iA projects the company will begin generating revenue from traumatic brain injury treatments in 2026 at $2 million, though it could reach as high as $58 million that year. With price appreciation also coming into play beginning with the 2027 fiscal year, Stellick’s probability adjusted revenue goes to $26 million by 2030, though it could have the potential to go as high as $659 million in that year.
Looking forward, Raymond James foresees a number of future catalysts for the company, including the release of top-line data in either April or May, a third quarter NDA filing with the U.S. Food and Drug Administration, with a goal of receiving clearance by the middle of 2023 ahead of an implied 2024 drug launch.
With shares of $ACOG.v at the lowest they are likely to be, now seems like a great time to get in before the company begins providing updates on its clinical studies.
$ACOG.v is currently trading at $1.03 and is valued at an MCAP of $63.34
iA Capital: https://www.cantechletter.com/2022/02/alpha-cognitions-2022-is-catalyst-rich-says-ia-capital/
Raymond James: https://www.cantechletter.com/2022/01/bet-on-alpha-cognition-in-the-alzheimers-space-says-raymond-james/#